Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology

被引:109
作者
Milane, Lara [1 ]
Ganesh, Shanthi [1 ]
Shah, Shruti [1 ]
Duan, Zhen-feng [2 ]
Amiji, Mansoor [1 ]
机构
[1] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA
关键词
Tumor hypoxia; Warburg's effect; Multidrug resistance; Cancer-initiating (stem) cells; Multifunctional nanoparticles; IN-VIVO REVERSAL; MULTIDRUG-RESISTANCE; CANCER-CELLS; P-GLYCOPROTEIN; BREAST-CANCER; TARGETED DELIVERY; RNA INTERFERENCE; GENE DELIVERY; SOLID TUMOR; GLUCOSYLCERAMIDE SYNTHASE;
D O I
10.1016/j.jconrel.2011.03.032
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Inefficiencies in systemic drug delivery and tumor residence as well as micro-environmental selection pressures contribute to the development of multidrug resistance (MDR) in cancer. Characteristics of MDR include abnormal vasculature, regions of hypoxia, up-regulation of ABC-transporters, aerobic glycolysis, and an elevated apoptotic threshold. Nano-sized delivery vehicles are ideal for treating MDR cancer as they can improve the therapeutic index of drugs and they can be engineered to achieve multifunctional parameters. The multifunctional ability of nanocarriers makes them more adept at treating heterogeneous tumor mass than traditional chemotherapy. Nanocarriers also have preferential tumor accumulation via the EPR effect; this accumulation can be further enhanced by actively targeting the biological profile of MDR cells. Perhaps the most significant benefit of using nanocarrier drug delivery to treat MDR cancer is that nanocarrier delivery diverts the effects of ABC-transporter mediated drug efflux; which is the primary mechanism of MDR. This review discusses the capabilities, applications, and examples of multifunctional nanocarriers for the treatment of MDR. This review emphasizes multifunctional nanocarriers that enhance drug delivery efficiency, the application of RNAi, modulation of the tumor apoptotic threshold, and physical approaches to overcome MDR. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:237 / 247
页数:11
相关论文
共 126 条
  • [1] Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes
    Altenberg, B
    Greulich, KO
    [J]. GENOMICS, 2004, 84 (06) : 1014 - 1020
  • [2] Hypoxia and cancer
    Brahimi-Horn, M. Christiane
    Chiche, Johanna
    Pouyssegur, Jacques
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2007, 85 (12): : 1301 - 1307
  • [3] Brizel DM, 1996, CANCER RES, V56, P941
  • [4] TUMOR HYPOXIA, DRUG-RESISTANCE, AND METASTASES
    BROWN, JM
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (05) : 338 - 339
  • [5] Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells
    Buys, Timon P. H.
    Chari, Raj
    Lee, Eric H. L.
    Zhang, May
    MacAulay, Calum
    Lam, Stephen
    Lam, Wan L.
    Ling, Victor
    [J]. GENES CHROMOSOMES & CANCER, 2007, 46 (12) : 1069 - 1079
  • [6] ABCB1 pharmacogenetics:: Progress, pitfalls, and promise
    Chinn, L. W.
    Kroetz, D. L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) : 265 - 269
  • [7] Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression
    Cosse, Jean-Philippe
    Michiels, Carine
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (07) : 790 - 797
  • [8] Nanoparticle therapeutics: an emerging treatment modality for cancer
    Davis, Mark E.
    Chen, Zhuo
    Shin, Dong M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (09) : 771 - 782
  • [9] The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic
    Davis, Mark E.
    [J]. MOLECULAR PHARMACEUTICS, 2009, 6 (03) : 659 - 668
  • [10] de Menezes DEL, 1998, CANCER RES, V58, P3320